Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 3 | 1 |
| List of Figures | 4 | 1 |
| Report Guidance | 5 | 1 |
| Clinical Trials by Region | 6 | 8 |
| Clinical Trials and Average Enrollment by Country | 7 | 2 |
| Top Five Countries Contributing to Clinical Trials in Asia-Pacific | 9 | 1 |
| Top Five Countries Contributing to Clinical Trials in Europe | 10 | 1 |
| Top Countries Contributing to Clinical Trials in North America | 11 | 1 |
| Top Countries Contributing to Clinical Trials in Middle East and Africa | 12 | 1 |
| Top Countries Contributing to Clinical Trials in Central and South America | 13 | 1 |
| Clinical Trials by G7 Countries: Proportion of Upper Limb Muscle Spasticity to Central Nervous System Clinical Trials | 14 | 1 |
| Clinical Trials by Phase in G7 Countries | 15 | 1 |
| Clinical Trials in G7 Countries by Trial Status | 16 | 1 |
| Clinical Trials by E7 Countries: Proportion of Upper Limb Muscle Spasticity to Central Nervous System Clinical Trials | 17 | 1 |
| Clinical Trials by Phase in E7 Countries | 18 | 1 |
| Clinical Trials in E7 Countries by Trial Status | 19 | 1 |
| Clinical Trials by Phase | 20 | 2 |
| In Progress Trials by Phase | 21 | 1 |
| Clinical Trials by Trial Status | 22 | 1 |
| Clinical Trials by End Point Status | 23 | 1 |
| Subjects Recruited Over a Period of Time | 24 | 1 |
| Clinical Trials by Sponsor Type | 25 | 1 |
| Prominent Sponsors | 26 | 3 |
| Top Companies Participating in Upper Limb Muscle Spasticity Therapeutics Clinical Trials | 27 | 2 |
| Prominent Drugs | 29 | 1 |
| Latest Clinical Trials News on Upper Limb Muscle Spasticity | 30 | 1 |
| Sep 15, 2016: Ipsen Biopharmaceuticals Announces Eight Presentations for Dysport (abobotulinumtoxinA) at the Annual Meeting of the American Association of Neuromuscular &Electrodiagnostic Medicine | 30 | 1 |
| Clinical Trial Profile Snapshots | 31 | 26 |
| Appendix | 57 | 3 |
| Abbreviations | 57 | 1 |
| Definitions | 57 | 1 |
| Research Methodology | 58 | 1 |
| Secondary Research | 58 | 1 |
| About GlobalData | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 59 | 1 |
| Source | 60 | 1 |
